Drop out patients (n=16) Patients ending the study (n=73) p-value (t student or χ²)
Age (yr) 62.4 ± 6.8 60.0 ± 3.0 0.532 a
Body mass index (kg/m2) 28.2 ± 1.9 27.6 ± 1.2 0.619 a
Number of men (n) 7 (43.8%) 48 (65.7%) 0.100 b
Social level (n)
1 9 (56.3%) 24 (32.9%) 0.211 b
2 2 (12.5%) 16 (21.9%)
3 5 (31.3%) 33 (45.2%)
Kidney failure (n) 2 (12.5%) 12 (16.4%) NA
Liver failure (n) 0 (0.0%) 1 (1.4%) NA
Number of total chronic disease (n)
1 2 (12.5%) 17 (23.3%) 0.324 b
2 7 (43.8%) 19 (26.0%)
>2 7 (43.8%) 37 (50.7%)
Number of diseases involved in the study (n)
1 13 (81.3%) 60 (82.2%) 0.929 b
Hypertension 6 (37.5%) 40 (54.8%) 0.202 b
Type 2 diabetes 5 (31.3%) 10 (13.7%)
Hypercholesterolemia 2 (12.5%) 10 (13.7%)
2 3 (18.8%) 12 (16.4%) 0.823 b
Hypertension + Type 2 diabetes 3 (18.8%) 9 (12.3%) 0.386 b
Hypertension + Hypercholesterolemia 0 (0.0%) 1 (1.4%) NA
Type 2 diabetes + Hypercholesterolemia 0 (0.0%) 2 (2.8%) NA
3 0 (0.0%) 1 (1.4%) NA
Number of different drugs prescribed 5.6 ± 1.5 5.6 ± 0,8 0.992 a
Adjusted number of different drugs prescribed (n)
<5 7 (43.8%) 29 (39.7%) 0.766 b
≥5 9 (56.3%) 44 (60.3%)
Side effects at the inclusion (n) 5 (31.3%) 15 (20.5%) 0.352 b
Adherence score at the inclusion 1.8 ± 0,6 2,1 ± 0,3 0.348 a
Patient with hypertension (n) 9 (56.3%) 51 (69.9%) 0.292 b
used as primary outcome 7 (43.8%) 49 (67.1%) 0.080 b
Patient with type II diabetes (n) 5 (31.3%) 22 (30.1%) 0.930 b
used as primary outcome 5 (31.3%) 11 (15.0%) 0.127 b
Patient with hypercholesterolemia (n) 5 (31.3%) 14 (19.2%) 0.286 b
used as primary outcome 4 (25%) 13 (17.8%) 0.507 b